9 Meters Biopharma (NMTR) – Accesswire
-
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
-
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023
-
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity
-
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
-
9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
-
9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
-
9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference
-
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome
-
9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy
-
9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022
-
9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific
-
9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
-
9 Meters Biopharma Announces 1-for-20 Reverse Stock Split
-
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome
-
9 Meters Biopharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) Congress
-
9 Meters Biopharma to Participate in the Citi 17th Annual BioPharma Conference
-
9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022
-
9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022
-
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
-
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
-
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
-
9 Meters Biopharma to Participate in the 2022 BIO International Convention
-
9 Meters Biopharma to Exhibit at Digestive Disease Week 2022
-
9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis
-
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022
-
9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium
-
9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease
-
9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic Conditions
-
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021
-
9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference
-
9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare Conference
-
9 Meters Biopharma Announces a Collaboration with NYU Langone Health Investigating NM-102 as a Potential Treatment for an Autoimmune Disorder
-
9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease
-
9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C)
-
9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference
-
9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
-
9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
-
9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences
-
9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications
-
9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bowel Syndrome Education
-
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021
-
9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator
-
9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
-
9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021
-
9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting
-
9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors
-
9 Meters Biopharma, Inc. Announces Partnership with Non-Profit Gluten-Free Food Pantry Organization Mend Hunger
-
9 Meters Biopharma, Inc. to Present at the Cantor Virtual Global Healthcare Conference
Back to NMTR Stock Lookup
